ChiCTR2100044471 版本V1.2 版本创建时间2021/09/20 05:15:24 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2100044471 

最近更新日期:

Date of Last Refreshed on:

2021-09-20 05:13:36 

注册时间:

Date of Registration:

2021-03-18 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

请于伦理委员会批准后才开始征募参试者,并与我们联系上传伦理批件。 基于行为决策双过程模型的助推策略在糖尿病生活方式干预中的有效性及机制研究

Public title:

Effectiveness and mechanism of nudge based on behavioral decision-making dual process model in diabetes lifestyle intervention: a cluster randomization study

注册题目简写:

English Acronym:

研究课题的正式科学名称:

基于行为决策双过程模型的助推策略在糖尿病生活方式干预中的有效性及机制研究

Scientific title:

Effectiveness and mechanism of nudge based on behavioral decision-making dual process model in diabetes lifestyle intervention: a cluster randomization study

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

张雅婷 

研究负责人:

李明子 

Applicant:

Yating Zhang 

Study leader:

Mingzi Li 

申请注册联系人电话:

Applicant telephone:

+86 18030251519

研究负责人电话:

Study leader's
telephone:

+86 13811795450

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

zhangyating_zoey@163.com

研究负责人电子邮件:

Study leader's E-mail:

limingzi2000@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

北京市海淀区学院路38号北京大学医学部

研究负责人通讯地址:

北京市海淀区学院路38号北京大学医学部

Applicant address:

38 Xueyuan Road, Haidian District, Beijing, China

Study leader's address:

38 Xueyuan Road, Haidian District, Beijing, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

北京大学护理学院

Applicant's institution:

School of Nursing, Peking University

研究负责人所在单位:

北京大学护理学院

Affiliation of the Leader:

School of Nursing, Peking University

是否获伦理委员会批准:

Approved by ethic committee:

No

伦理委员会批件文号:

Approved No. of ethic committee:

伦理委员会批件附件:

Approved file of Ethical Committee:

批准本研究的伦理委员会名称:

Name of the ethic committee:

伦理委员会批准日期:

Date of approved by ethic committee:

2013-08-26 00:00:00

伦理委员会联系人:

Contact Name of the ethic committee:

伦理委员会联系地址:

Contact Address of the ethic committee:

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

北京大学护理学院

Primary sponsor:

School of Nursing, Peking University

研究实施负责(组长)单位地址:

北京市海淀区学院路38号北京大学医学部

Primary sponsor's address:

Peking University Health Science Center, 38 Xueyuan Road, Haidian District, Beijing, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

北京

市(区县):

海淀区

Country:

China

Province:

Beijing

City:

Haidian District

单位(医院):

北京大学护理学院

具体地址:

学院路38号

Institution
hospital:

School of Nursing, Peking University

Address:

38 Xueyuan Road

经费或物资来源:

国家自然科学基金会

Source(s) of funding:

The National Natural Science Foundation of China

研究疾病:

2型糖尿病  

Target disease:

type 2 diabetes

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

整群随机分组 

Study design:

Cluster randomization 

研究目的:

(1)建立一套聚焦于2型糖尿病患者饮食干预的、基于心理学双过程理论的、适合在社区开展的完整的助推干预方案; (2)实现助推干预方案在社区糖尿病管理中的应用,并进行有效性的临床验证; (3)阐释助推策略发挥作用的可能的脑神经机制。  

Objectives of Study:

(1) To establish a complete community nudge intervention program that focuses on diet intervention for patients with type 2 diabetes and is based on psychological dual-process theory; (2) To realize the application of nudge intervention program in the management of diabetes in the community, and to conduct clinical verification of its effectiveness; (3) To explain the possible neural mechanism of nudging strategies.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

①符合《中国2型糖尿病防治指南2017版》制定的2型糖尿病诊断标准;
②年龄在18-60岁;
③BMI≥24kg/m2;
④未来2年内居住在北京
⑤知情同意

Inclusion criteria

1. It meets the diagnostic criteria for type 2 diabetes formulated in China Guidelines for the Prevention and Treatment of Type 2 Diabetes (2017 Edition);
2. aged between 18 and 60 years;
3. BMI 24 kg/m2;
4. Live in Beijing in the next 2 years;
5. Informed consent.

排除标准:

① 合并严重心、脑、肾、眼、足和神经系统并发症(增殖性视网膜病,肾病IV期以上或者肌酐>2mg/dl,心功能III级以下,有脑血管意外后遗症,糖尿病足I级以上);
② 目前采用胰岛素等注射类降糖药物治疗;
③ 有精神异常、认知障碍、不能合作者;
④ 正在参加其他研究课题的患者。

Exclusion criteria:

① Complications of serious heart, brain, kidney, eye, foot and nervous system complications (proliferative retinopathy, nephropathy above stage IV or creatinine >2mg/ dL, heart function below grade III, sequelae of cerebrovascular accident, diabetic foot above grade I);
② At present, insulin and other injectable hypoglycemic drugs are used for treatment;
③have mental disorder, cognitive impairment, unable to cooperate;
④ patients who are participating in other research projects.

研究实施时间:

Study execute time:

From 2020-01-01 00:00:00 To 2023-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2021-04-01 00:00:00 To 2021-09-01 00:00:00

干预措施:

Interventions:

组别:

助推课程组

样本量:

117

Group:

Group of nudge course

Sample size:

干预措施:

4次助推课程干预

干预措施代码:

Intervention:

4 times nudge course interventions

Intervention code:

组别:

助推餐具包组

样本量:

117

Group:

Group of nudge tableware

Sample size:

干预措施:

3个月助推餐具使用

干预措施代码:

Intervention:

3months nudge tableware interventions

Intervention code:

组别:

助推课程加餐具包组

样本量:

117

Group:

Group of nudge course plus tableware

Sample size:

干预措施:

4次助推课程干预和3个月助推餐具包使用

干预措施代码:

Intervention:

4 nudge course interventions and 3 months of nudge tableware use

Intervention code:

组别:

标准课程组

样本量:

117

Group:

group of strandard course

Sample size:

干预措施:

4次标准课程干预

干预措施代码:

Intervention:

4 times standard course interventions

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

北京 

市(区县):

 

Country:

China

Province:

Beijing

City:

单位(医院):

京煤集团总医院 

单位级别:

三级乙等 

Institution
hospital:

Beijing Coal Group General Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

糖化血红蛋白

指标类型:

主要指标

Outcome:

HbA1c

Type:

Primary indicator

测量时间点:

基线,干预后3,6,12,18,24个月

测量方法:

抽血

Measure time point of outcome:

baseline, 3, 6, 12, 18, 24 months after intervention

Measure method:

Laboratory examination

指标中文名:

行为改变

指标类型:

次要指标

Outcome:

behavior change

Type:

Secondary indicator

测量时间点:

基线,干预后3,6,12,18,24个月

测量方法:

问卷

Measure time point of outcome:

baseline, 3, 6, 12, 18, 24 months after intervention

Measure method:

questionnaire

指标中文名:

糖尿病痛苦

指标类型:

次要指标

Outcome:

diabetes distress

Type:

Secondary indicator

测量时间点:

基线,干预后3,6,12,18,24个月

测量方法:

问卷(DDS-17)

Measure time point of outcome:

baseline, 3, 6, 12, 18, 24 months after intervention

Measure method:

questionnaire (DDS-17)

指标中文名:

抑郁

指标类型:

次要指标

Outcome:

depression

Type:

Secondary indicator

测量时间点:

基线,干预后3,6,12,18,24个月

测量方法:

问卷(PHQ-9)

Measure time point of outcome:

baseline, 3, 6, 12, 18, 24 months after intervention

Measure method:

questionnaire(PHQ-9)

指标中文名:

生活质量

指标类型:

次要指标

Outcome:

quality of life

Type:

Secondary indicator

测量时间点:

基线,干预后3,6,12,18,24个月

测量方法:

问卷(EQ-5D)

Measure time point of outcome:

baseline, 3, 6, 12, 18, 24 months after intervention

Measure method:

questionnaire(EQ-5D)

指标中文名:

血压

指标类型:

次要指标

Outcome:

blood pressure

Type:

Secondary indicator

测量时间点:

基线,干预后3,6,12,18,24个月

测量方法:

电子血压计

Measure time point of outcome:

baseline, 3, 6, 12, 18, 24 months after intervention

Measure method:

Electronic sphygmomanometer

指标中文名:

BMI

指标类型:

次要指标

Outcome:

BMI

Type:

Secondary indicator

测量时间点:

基线,干预后3,6,12,18,24个月

测量方法:

体重计和身高仪

Measure time point of outcome:

baseline, 3, 6, 12, 18, 24 months after intervention

Measure method:

The scale and height meter

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

手臂静脉

Sample Name:

blood

Tissue:

vein

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

随机分组方案由1名研究助理(不参与干预实施、数据采集和分析)通过SPSS进行区组随机分组产生,具体操作步骤为首先用1-12数字代表各个站点名称,其次用随机数字生成器生成种子20210312,接着用随机函数生成12个0-1之间的随机数,最后通过可视分箱化将12个随机数等分成3组,每组4个随机数。

Randomization Procedure (please state who generates the random number sequence and by what method):

Random grouping scheme by one research assistant (not interfering in implementation, data acquisition and analysis) by SPSS a block of random grouping, specific operation steps 1-12 Numbers for each site for first name, second use random number generator to generate seed 20210312, with random function to generate&#

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

向研究课题组联系索取

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Contact the research team for a request

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

数据的采集通过定期随访填写纸质病例记录表(CRF),数据的管理统一由课题组成员回收保存。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Data were collected through regular follow-up and paper case record form (CRF) was filled in. Data management was unified by the members of the research group to recover and save.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2021-03-18 14:17:58